Home Liver DiseasesLiver Cancer Mac-2-binding protein glycan isomer enhances the aggressiveness of hepatocellular carcinoma by activating mTOR signaling

Mac-2-binding protein glycan isomer enhances the aggressiveness of hepatocellular carcinoma by activating mTOR signaling

Credits to the Source Link Daniel
Mac-2-binding protein glycan isomer enhances the aggressiveness of hepatocellular carcinoma by activating mTOR signaling
  • 1.

    Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A. & Jemal, A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68, 394–424 (2018).

    Article 

    Google Scholar
     

  • 2.

    Blachier, M., Leleu, H., Peck-Radosavljevic, M., Valla, D. C. & Roudot-Thoraval, F. The burden of liver disease in Europe: a review of available epidemiological data. J. Hepatol. 58, 593–608 (2013).

    Article 

    Google Scholar
     

  • 3.

    Greten, T. F., Papendorf, F., Bleck, J. S., Kirchhoff, T., Wohlberedt, T., Kubicka, S. et al. Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients. Br. J. Cancer 92, 1862–1868 (2005).

    CAS 
    Article 

    Google Scholar
     

  • 4.

    Mohkam, K., Dumont, P. N., Manichon, A. F., Jouvet, J. C., Boussel, L., Merle, P. et al. No-touch multibipolar radiofrequency ablation vs. surgical resection for solitary hepatocellular carcinoma ranging from 2 to 5 cm. J. Hepatol. 68, 1172–1180 (2018).

    Article 

    Google Scholar
     

  • 5.

    Kamarajah, S. K. Fibrosis score impacts survival following resection for hepatocellular carcinoma (HCC): a surveillance, end results and epidemiology (SEER) database analysis. Asian J. Surg. 41, 551–561 (2018).

    Article 

    Google Scholar
     

  • 6.

    Kuno, A., Ikehara, Y., Tanaka, Y., Ito, K., Matsuda, A., Sekiya, S. et al. A serum “sweet-doughnut” protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis. Sci. Rep. 3, 1065 (2013).

    Article 

    Google Scholar
     

  • 7.

    Hasegawa, K., Takata, R., Nishikawa, H., Enomoto, H., Ishii, A., Iwata, Y. et al. Impact of Wisteria floribunda agglutinin-positive Mac-2-binding protein in patients with hepatitis C virus-related compensated liver cirrhosis. Int. J. Mol. Sci. 17, 1500 (2016).

    Article 

    Google Scholar
     

  • 8.

    Nishikawa, H., Enomoto, H., Iwata, Y., Kishino, K., Shimono, Y., Hasegawa, K. et al. Clinical significance of serum Wisteria floribunda agglutinin positive Mac-2-binding protein level in non-alcoholic steatohepatitis. Hepatol. Res. 46, 1194–1202 (2016).

    CAS 
    Article 

    Google Scholar
     

  • 9.

    Nishikawa, H., Hasegawa, K., Ishii, A., Takata, R., Enomoto, H., Yoh, K. et al. A proposed predictive model for advanced fibrosis in patients with chronic hepatitis B and its validation. Medicine (Baltimore) 95, e4679 (2016).

    CAS 
    Article 

    Google Scholar
     

  • 10.

    Toshima, T., Shirabe, K., Ikegami, T., Yoshizumi, T., Kuno, A., Togayachi, A. et al. A novel serum marker, glycosylated Wisteria floribunda agglutinin-positive Mac-2 binding protein (WFA(+)-M2BP), for assessing liver fibrosis. J. Gastroenterol. 50, 76–84 (2015).

    CAS 
    Article 

    Google Scholar
     

  • 11.

    Umemura, T., Joshita, S., Sekiguchi, T., Usami, Y., Shibata, S., Kimura, T. et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts Liver fibrosis and prognosis in primary biliary cirrhosis. Am. J. Gastroenterol. 110, 857–864 (2015).

    CAS 
    Article 

    Google Scholar
     

  • 12.

    Kim, S. U., Heo, J. Y., Kim, B. K., Park, J. Y., Kim, D. Y., Han, K. H. et al. Wisteria floribunda agglutinin-positive human Mac-2 binding protein predicts the risk of HBV-related liver cancer development. Liver Int. 37, 879–887 (2017).

    CAS 
    Article 

    Google Scholar
     

  • 13.

    Sato, S., Genda, T., Ichida, T., Amano, N., Sato, S., Murata, A. et al. Prediction of hepatocellular carcinoma development after hepatitis C virus eradication using serum wisteria floribunda agglutinin-positive Mac-2-binding protein. Int. J. Mol. Sci. 17, 2143 (2016).

    Article 

    Google Scholar
     

  • 14.

    Shirabe, K., Bekki, Y., Gantumur, D., Araki, K., Ishii, N., Kuno, A. et al. Mac-2 binding protein glycan isomer (M2BPGi) is a new serum biomarker for assessing liver fibrosis: more than a biomarker of liver fibrosis. J. Gastroenterol. 53, 819–826 (2018).

    CAS 
    Article 

    Google Scholar
     

  • 15.

    Toyoda, H., Kumada, T., Tada, T., Kaneoka, Y., Maeda, A., Korenaga, M. et al. Serum WFA+ -M2BP levels as a prognostic factor in patients with early hepatocellular carcinoma undergoing curative resection. Liver Int. 36, 293–301 (2016).

    CAS 
    Article 

    Google Scholar
     

  • 16.

    Bekki, Y., Yoshizumi, T., Shimoda, S., Itoh, S., Harimoto, N., Ikegami, T. et al. Hepatic stellate cells secreting WFA(+) -M2BP: Its role in biological interactions with Kupffer cells. J. Gastroenterol. Hepatol. 32, 1387–1393 (2017).

    CAS 
    Article 

    Google Scholar
     

  • 17.

    Klover P. J., Thangapazham R. L., Kato J., Wang J. A., Anderson S. A., Hoffmann V. et al. Tsc2 disruption in mesenchymal progenitors results in tumors with vascular anomalies overexpressing Lgals3. Elife. 6, e23202 (2017).

  • 18.

    Yoo, B. C., Hong, S. H., Ku, J. L., Kim, Y. H., Shin, Y. K., Jang, S. G. et al. Galectin-3 stabilizes heterogeneous nuclear ribonucleoprotein Q to maintain proliferation of human colon cancer cells. Cell Mol. Life Sci. 66, 350–364 (2009).

    CAS 
    Article 

    Google Scholar
     

  • 19.

    Jiang, S. S., Weng, D. S., Wang, Q. J., Pan, K., Zhang, Y. J., Li, Y. Q. et al. Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J. Transl. Med. 12, 273 (2014).

    Article 

    Google Scholar
     

  • 20.

    K., H. D., DC, A., George, J. K. C., Jung‐Ta, C., Ri‐Yao, Y. & Fu‐Tong, L. Galectin‐3 expression is induced in cirrhotic liver and hepatocellular carcinoma. Int. J. Cancer 81, 519–526 (1999).

    Article 

    Google Scholar
     

  • 21.

    Matsuda, Y., Yamagiwa, Y., Fukushima, K., Ueno, Y. & Shimosegawa, T. Expression of galectin-3 involved in prognosis of patients with hepatocellular carcinoma. Hepatol. Res. 38, 1098–1111 (2008).

    CAS 
    Article 

    Google Scholar
     

  • 22.

    Tsukagoshi, M., Araki, K., Yokobori, T., Altan, B., Suzuki, H., Kubo, N. et al. Overexpression of karyopherin-α2 in cholangiocarcinoma correlates with poor prognosis and gemcitabine sensitivity via nuclear translocation of DNA repair proteins. Oncotarget 8, 42159–42172 (2017).

    Article 

    Google Scholar
     

  • 23.

    Luo, D., Yi, Y., Peng, K., Liu, T., Yang, J., Liu, S. et al. Oridonin derivatives as potential anticancer drug candidates triggering apoptosis through mitochondrial pathway in the liver cancer cells. Eur. J. Med Chem. 178, 365–379 (2019).

    CAS 
    Article 

    Google Scholar
     

  • 24.

    Guzelcan, E. A., Baxendale, I. R., Cetin-Atalay, R. & Baumann, M. Synthesis of new derivatives of boehmeriasin A and their biological evaluation in liver cancer. Eur. J. Med Chem. 166, 243–255 (2019).

    CAS 
    Article 

    Google Scholar
     

  • 25.

    Haberle, V., Forrest, A. R., Hayashizaki, Y., Carninci, P. & Lenhard, B. CAGEr: precise TSS data retrieval and high-resolution promoterome mining for integrative analyses. Nucleic Acids Res. 43, e51 (2015).

    Article 

    Google Scholar
     

  • 26.

    Frith, M. C., Saunders, N. F., Kobe, B. & Bailey, T. L. Discovering sequence motifs with arbitrary insertions and deletions. PLoS Comput. Biol. 4, e1000071 (2008).

    Article 

    Google Scholar
     

  • 27.

    Koths, K., Taylor, E., Halenbeck, R., Casipit, C. & Wang, A. Cloning and characterization of a human Mac-2-binding protein, a new member of the superfamily defined by the macrophage scavenger receptor cysteine-rich domain. J. Biol. Chem. 268, 14245–14249 (1993).

    CAS 
    PubMed 

    Google Scholar
     

  • 28.

    Narimatsu, H. Development of M2BPGi: a novel fibrosis serum glyco-biomarker for chronic hepatitis/cirrhosis diagnostics. Expert Rev. Proteomics 12, 683–693 (2015).

    CAS 
    Article 

    Google Scholar
     

  • 29.

    van Meer, S., van Erpecum, K. J., Sprengers, D., Coenraad, M. J., Klumpen, H. J., Jansen, P. L. et al. Hepatocellular carcinoma in cirrhotic versus noncirrhotic livers: results from a large cohort in the Netherlands. Eur. J. Gastroenterol. Hepatol. 28, 352–359 (2016).

    Article 

    Google Scholar
     

  • 30.

    Grassadonia, A., Tinari, N., Iurisci, I., Piccolo, E., Cumashi, A., Innominato, P. et al. 90K (Mac-2 BP) and galectins in tumor progression and metastasis. Glycoconj. J. 19, 551–556 (2002).

    CAS 
    Article 

    Google Scholar
     

  • 31.

    Inohara, H., Akahani, S., Koths, K. & Raz, A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res. 56, 4530–4534 (1996).

    CAS 
    PubMed 

    Google Scholar
     

  • 32.

    Wu, K. L., Huang, E. Y., Jhu, E. W., Huang, Y. H., Su, W. H., Chuang, P. C. et al. Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway. J. Gastroenterol. 48, 350–359 (2013).

    CAS 
    Article 

    Google Scholar
     

  • 33.

    Lin, L., Han, M. M., Wang, F., Xu, L. L., Yu, H. X. & Yang, P. Y. CXCR7 stimulates MAPK signaling to regulate hepatocellular carcinoma progression. Cell Death Dis. 5, e1488 (2014).

    CAS 
    Article 

    Google Scholar
     

  • 34.

    Bao, J., Walliander, M., Kovacs, F., Nagaraj, A. S., Hemmes, A., Sarhadi, V. K. et al. Spa-RQ: an image analysis tool to visualise and quantify spatial phenotypes applied to non-small cell lung cancer. Sci. Rep. 9, 17613 (2019).

    Article 

    Google Scholar
     

  • 35.

    Duvoux, C. & Toso, C. mTOR inhibitor therapy: Does it prevent HCC recurrence after liver transplantation? Transpl. Rev. (Orlando) 29, 168–174 (2015).

    Article 

    Google Scholar
     

  • 36.

    Koeberle, D., Dufour, J. F., Demeter, G., Li, Q., Ribi, K., Samaras, P. et al. Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann. Oncol. 27, 856–861 (2016).

    CAS 
    Article 

    Google Scholar
     

  • 37.

    Okuno T., Kakehashi A., Ishii N., Fujioka M., Gi M. & Wanibuchi H. mTOR Activation in liver tumors is associated with metabolic syndrome and non-alcoholic steatohepatitis in both mouse models and humans. Cancers (Basel). 10, 465 (2018).

  • 38.

    Wang, C., Cigliano, A., Delogu, S., Armbruster, J., Dombrowski, F., Evert, M. et al. Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer. Cell Cycle 12, 1999–2010 (2013).

    CAS 
    Article 

    Google Scholar
     

  • 39.

    Wang, S., Zhu, M., Wang, Q., Hou, Y., Li, L., Weng, H. et al. Alpha-fetoprotein inhibits autophagy to promote malignant behaviour in hepatocellular carcinoma cells by activating PI3K/AKT/mTOR signalling. Cell Death Dis. 9, 1027 (2018).

    Article 

    Google Scholar
     

  • 40.

    Zhu, A. X., Chen, D., He, W., Kanai, M., Voi, M., Chen, L. T. et al. Integrative biomarker analyses indicate etiological variations in hepatocellular carcinoma. J. Hepatol. 65, 296–304 (2016).

    CAS 
    Article 

    Google Scholar
     

  • Source Link

    Related Articles

    Leave a Comment

    This website uses cookies to improve your experience. We will assume you are ok with this, but you can opt-out if you wish. Accept Read More

    %d bloggers like this: